We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics... read more Featured Products: More products

Download Mobile App




Inflammatory Cytokines Measured in Infants Born to Preterm Preeclamptic Mothers

By LabMedica International staff writers
Posted on 29 Nov 2021
Print article
Image: The Luminex 200 Instrument System sets the standard for multiplexing, providing the ability to perform up to 100 different tests in a single reaction volume on a flow cytometry-based platform (Photo courtesy of Luminex Corp)
Image: The Luminex 200 Instrument System sets the standard for multiplexing, providing the ability to perform up to 100 different tests in a single reaction volume on a flow cytometry-based platform (Photo courtesy of Luminex Corp)
Preeclampsia is both a vascular and inflammatory disorder. The pathophysiology of preeclampsia is complex and rooted in the interplay between maternal and placental factors with the key characteristics of maternal inflammation and vascular etiologies.

The maternal pathophysiology impacts fetal physiology through the filter of the placenta. Triggers of the fetal inflammatory response are not completely understood, as there is contradictory evidence as to whether cytokines directly cross the placenta-blood barrier and emerge on the fetal side or if the fetal inflammatory response is indirectly triggered.

Clinical Scientists at the University of Colorado Anschutz Medical Campus (Aurora, CO, USA) conducted a prospective inceptional cohort study of preterm preeclampsia from July 1, 2010, through June 30, 2012. Eighty-one maternal-newborn dyads were examined. Placentas were analyzed for inflammatory and vascular pathologies. Neurodevelopmental assessment of infants utilizing the Pediatric Stroke Outcome Measure (PSOM) was conducted at 6-month corrected gestational age.

Maternal venous blood samples were collected at time of enrollment and within two hours after delivery. Fetal cord blood venous samples were obtained immediately after delivery by trained perinatal nurses with experience in venous cord blood collection. Platelet-poor plasma was aliquoted, frozen, and sent for cytokine analysis (IL-1β, IL-6, IL-8, and TNF-α) via the Luminex multicode assay platform (Luminex Corp, Austin, TX, USA). Placenta analysis assessments were conducted by a placental pathologist.

The investigators reported that worse neurological outcomes were not associated with elevated maternal / fetal cytokines. Early preterm birth (gestational age ≤ 32 weeks) was associated with worse neurological outcomes at 6-months regardless of maternal/ fetal cytokine levels, placental pathology, or cranial ultrasound findings (OR 1.70). When correcting for gestational age, elevated IL-6 approached significance as a predictor for worse developmental outcome (OR 1.025 ). Pathological evidence of maternal malperfusion and worse outcomes were noted in early preterm, although the sample size was small. When chronic villitis was present (N = 5), higher maternal levels of IL-6 (N = 3; 60%) were usually present rather than in fetal cord blood. Although only three cases of histologic fetal inflammatory response were seen, both IL-6 and IL-8 were elevated in the fetal cord blood (N = 2; 67%), but not elevated in maternal samples.

The authors concluded that their study supports the distinction that 32-weeks gestational age (‘moderate preterm) is a turning point for improved neurological outcomes. They found that cranial ultrasounds were unhelpful in predicting risk in this pre-eclamptic population. The data suggest that maternal placental malperfusion at earlier gestational age may be an underlying factor associated with poor neurological outcomes, although more robust studies are warranted. Neither elevated cytokines nor “male disadvantage” was associated with adverse neurological outcomes. The study was published on November 15, 2021 in the journal PloS One.

Related Links:
University of Colorado Anschutz Medical Campus
Luminex Corp


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.